Dataset Information

HIV-1 Nef protein promotes the proliferation of lymphoma cells by activating the NF-κB pathway

ABSTRACT: The prevalence of lymphoma in people living with HIV is remarkably higher compared to that of the general population, and the overall survival is markedly lower compared to that of lymphoma patients without HIV. In this study, we have demonstrated that the HIV-encoded negative regulatory factor (Nef) directly promotes lymphoma cell proliferation. We have also observed that Nef significantly upregulates key genes and proteins of the NF-κB signaling pathway, thereby promoting growth of lymphoma cells. These observations underscore the increasingly recognized role of HIV-encoded proteins as oncogenic drivers, providing fundamental mechanistic insights into the manner in which viral factors exploit host signaling networks to fuel lymphomagenesis.

ORGANISM(S): Homo Sapiens

SUBMITTER: Yemiao Chen

PROVIDER: PXD072199 | iProX | Fri Dec 19 00:00:00 GMT 2025

REPOSITORIES: iProX

ACCESS DATA

Similar Datasets

Project description:Sporadic Burkitt lymphoma (sBL) can be delineated from diffuse large B-cell lymphoma (DLBCL) by a very homogeneous mRNA expression signature. However, it remained unclear whether all three BL variants – sBL, endemic BL (eBL) and immunodeficiency-associated BL (HIV-BL) – represent a uniform biological entity despite their differences in geographical occurrence, association with immunodeficiency and/or incidence of EBV infection. To address this issue, we generated micro RNA (miRNA) profiles from 18 eBL, 31 sBL and 15 HIV-BL cases. In addition, we analyzed the miRNA expression of 86 DLBCL to determine whether miRNA profiles recapitulate the molecular differences between BL and DLBCL evidenced by mRNA profiling. A signature of 38 miRNAs enriched in MYC regulated and NF-kB pathway associated miRNAs was obtained that differentiated BL from DLBCL. The miRNA profiles of sBL and eBL displayed only 6 differentially expressed miRNAs, whereas HIV and EBV infection had no impact on the miRNA profile of BL. In conclusion, miRNA profiling confirms that BL and DLBCL represent distinct lymphoma categories and demonstrates that the three BL variants are representatives of the same biological entity with only marginal miRNA expression differences between eBL and sBL. Archival tumor specimens of 86 diffuse large B-cell lymphoma (DLBCL) and 64 Burkitt lymphoma (BL) patients were obtained. The DLBCL samples have previously been reviewed by a panel of expert hematopathologists and their clinical data were published as part of the RiCOVER-60 trial. The diagnosis of all BL cases was confirmed by histopathology review according to the criteria of the WHO classification. Based on their geographical origin, 31 BL samples were designated as sporadic BL (sBL) and 18 samples as endemic BL (eBL). Fifteen BL cases were diagnosed as immunodeficiency-associated BL (HIV-BL). Of the 18 eBL 14 cases were EBV+ (87.5%), 2 samples were EBV- (12.5%) and for 2 eBL cases the EBV status was unknown. Of the sBL samples 26 were EBV- (86.7%), 4 cases were EBV+ (13.3%) and for 1 case the EBV status was not evaluable. Among the HIV-BL 5 (33.3%) were EBV+, whereas 10 (66.7%) were EBV-.

Dataset Information

HIV-1 Nef protein promotes the proliferation of lymphoma cells by activating the NF-κB pathway

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets